Medical Services Law Update


Pfizer Settles Claims for Promoting Off Label Drug Use


8:38 am
In a settlement with the Justice and Health and Human Services Departments announced Wednesday Pfizer agreed to plead guilty to a criminal charge and the company will pay $1.3 billion to resolve claims relating to off-label marketing of the pain killer Bextra. Pfizer agreed to pay another $1 billion to resolve whistleblower complaints that it illegally promoted Bextra, Geodon, the antibiotic Zyvox and the epilepsy drug Lyrica.  Pfizer allegedly treated doctors to meals, paid them for speaking engagements and subsidized their travel to induce them to prescribe off-label uses for those four drugs and nine others. The settlement is the third in which Pfizer signed a “corporate integrity” agreement pledging to clean up its drug-marketing practices. It signed previous agreements in 2002 over Lipitor and in 2004 over  Neurontin. Under the latest agreement, Pfizer will have to create a mechanism for doctors to report questionable conduct by Pfizer sales representatives.

Missed Cancer Diagnoses Net Plaintiffs Big Verdicts

A Tennesse jury returned a $23,600,000 verdict for a woman and her husband in a failure to diagnose breast cancer case.  The plaintiff was 23 years old when she first informed her Ob/Gyn of a breast lump in July 2003.  She was advised to wait to be seen until her scheduled appointment in August.  At that appointment her doctor examined the lump and classified it as a cyst or fatty deposit that was “nothing to worry about.”  No testing was ordered, and the doctor did not document her findings or any plan to re-examine the lump at subsequent visits.  A January 25, 2005 exam revealed a suspicious lump.  A mammogram and ultrasound showed a cancerous mass.  On February 14, 2005 the plaintiff was diagnosed with stage IV cancer, which had metastisized to her liver and lungs.  The plaintiff's oncology expert opined that the lump reported in July 2003 was most likely Stage I cancer with a 95 % cure rate which progressed to incurable Stage IV cancer by the time of diagnosis in February of 2005.
In Texas, a jury returned a $3.5 million verdict for the estate of a woman who  died of cancer that her PCP had misdiagnosed as a sebaceous cyst a year and a half before the cancer was properly diagnosed.  In the Texas case the jury apportioned 10% of the fault to the plaintiff for waiting to have the lump on her head examined given her family’s history of cancer.   The $3.5 million award will be reduced to $1.5 million pursuant to a Texas law that limits the amount that can be recovered for non-economic damages.
Trend: states adopting a uniform medical license application

The AMA’s AmedNews reports on a trend in medical licensure: professionals seeking to practice in multiple states can increasingly use a uniform application.  This saves time, cuts down on potential clerical errors, and promotes consistency.
The Federation of State Medical Boards developed the form as part of a federally-funded project aimed at fostering “license portability.”  The program benefits doctors who train in one state as residents, in another as fellows, and then take permanent jobs in yet another.  It also benefits practices near state lines, which often have facilities straddling state lines.  The trend is seen as an important adjunct to the growing trend in “telemedicine.”
Seventeen states now use it.  Idaho reported shorter approval times (66 days down to 44, on average).  This is in part attributed to its online application process – a related innovation which is finding increased acceptance.

Blogs

Online journals concerning specific industries, hosted by one of our attorneys, with regular entries of commentary and descriptions of relevant events.


Our News

First Annual NKMS Puppy Party for All Dog Loving Employees & Friends Of The Firm
[7/29/2010]

Chambers USA 2010 Recognizes Four NKMS Attorneys As Among The Nation's Best
[6/15/2010]

NKMS attorneys edit and author A Practical Guide to Evidence in New Hampshire
[6/8/2010]


Subscribe to
NKMS updates

Keep informed about developments in the areas of the law that concern you. Subscribe to our series of e-alerts and newsletters here.